305 related articles for article (PubMed ID: 25831219)
1. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
[TBL] [Abstract][Full Text] [Related]
2. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
[TBL] [Abstract][Full Text] [Related]
5. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
8. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Friedland G; Khoo S; Jack C; Lalloo U
J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
[TBL] [Abstract][Full Text] [Related]
10. Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.
Mugusi S; Habtewold A; Ngaimisi E; Amogne W; Yimer G; Minzi O; Makonnen E; Sudfeld C; Burhenne J; Aklillu E
Front Pharmacol; 2020; 11():26. PubMed ID: 32116703
[TBL] [Abstract][Full Text] [Related]
11. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
Mariana N; Purwantyastuti ; Instiaty ; Rusli A
Acta Med Indones; 2016 Jan; 48(1):10-6. PubMed ID: 27241539
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076
[TBL] [Abstract][Full Text] [Related]
13. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
Naidoo A; Chirehwa M; McIlleron H; Naidoo K; Essack S; Yende-Zuma N; Kimba-Phongi E; Adamson J; Govender K; Padayatchi N; Denti P
J Antimicrob Chemother; 2017 May; 72(5):1441-1449. PubMed ID: 28175315
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
[TBL] [Abstract][Full Text] [Related]
16. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C
J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753
[TBL] [Abstract][Full Text] [Related]
17. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Sathia L; Obiorah I; Taylor G; Kon O; O'Donoghue M; Gibbins S; Walsh J; Winston A
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
[TBL] [Abstract][Full Text] [Related]
18. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
19. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
